Constricting deals

Raising money

Improve relationships with staff, stabilize supply chain

By Jacqueline Howard | CNN

The U.S. Food and Drug Administration has approved a blood test to screen for colon cancer in adults aged 45 and older who’re at average risk.

The test's maker, Palo Alto-based biotechnology company Guardant Health, announced Monday that it’s the first blood test approved by the FDA as a primary screening option for colon cancer and that it’s the first approved blood screening test for colon cancer that meets the necessities for Medicare reimbursement. For patients with private medical insurance, the fee of the test may vary depending on individual insurance plan coverage. The list price for the test has not yet been announced.

“This is a promising step toward providing more convenient tools for early detection of colon cancer while making it easier to treat,” said Dr. William M. Grady, a gastroenterologist on the Fred Hutchinson Cancer Center. Guardant Health said in a press release on Monday.

In the United States, colon cancer is the second leading reason behind cancer deaths. More than 53,000 persons are expected to die from the disease this yr, in accordance with the American Cancer Society. But over 70% of deaths from colon cancer may be prevented by increased screening.

The test, called Shield, is predicted to hit the market next week and can be an option that healthcare providers can offer their patients alongside other methods of screening for colon and rectal cancer, including colonoscopies and residential stool tests. An easy blood test could also be more convenient for some patients, while colonoscopies may be invasive or home stool tests may be uncomfortable.

“The test, which has similar accuracy in detecting colon cancer as stool tests for early cancer detection, could provide an alternative for patients who would otherwise decline current screening options,” Grady said within the press release.

Current colon cancer screening options for people at average risk include a stool test yearly or every three years, a standard colonoscopy every 10 years, a virtual colonoscopy every five years, or a sigmoidoscopy every five years, which uses a tube-shaped instrument called an endoscope to look at the lower a part of the colon.

It is estimated that multiple in three adults aged 50 to 75 don’t attend preventive screenings as really helpful. National Roundtable on Colon CancerThe US Preventive Services Task Force recommends Screening for colon cancer begins at age 45 for individuals with average risk.

“The persistent gap in colorectal cancer screening rates shows that existing screening options are not attractive to millions of people,” said Dr. Daniel Chung, a gastroenterologist at Massachusetts General Hospital and professor of medication at Harvard Medical School, in a press release released Monday by Guardant Health.

“The FDA's approval of the Shield blood test is a tremendous step forward and offers a compelling new solution to fill this gap. This decision will help make screening tests more widely available,” Chung said. “With increased screening rates and early cancer detection, many more lives can be saved.”

In the United States, about 1 in 23 men and 1 in 25 women will develop colon cancer during their lifetime.

The Schild blood test was already available as a laboratory-developed test, or LDT, prior to FDA approval, however the agency's approval could make the test more widely available and supply broader coverage as one other primary screening option. The current self-pay price for the LDT version of the test is $895.

In May, the FDA published Panel on Molecular and Clinical Genetics of the Medical Devices Advisory Committee The authors voted 8 to 1 that the Shield test is protected in individuals who meet the standards for testing, 6 to three that the test is effective in individuals who meet the standards, and seven to 2 that the advantages of the test outweigh the risks.

The Shield test detects tumor DNA in blood samples and The doctor would need to order the test and kit for his patient.

In a study of just about 8,000 participants conducted in March New England Journal of Medicine. Sensitivity refers to the flexibility of a test to accurately discover diseased individuals and label them as positive. Specificity refers to the flexibility to accurately label diseased individuals as negative.

The study found that about 83% of participants diagnosed with colon cancer by colonoscopy tested positive for the disease using the Shield test, compared with about 17% who had a false negative result.

The test showed a sensitivity of about 88% in detecting stage I, II or III colon cancer and a lower sensitivity of about 13% in detecting precancerous changes.

About 90 percent of study participants without advanced colon cancer or precancerous changes had a negative blood test result, compared with about 10 percent who had a false positive test result.

In addition, several research teams and corporations are working on developing easy blood tests to detect colon and rectal cancer.

A blood test, unlike a colonoscopy, cannot discover worrisome lesions or polyps within the colon or rectum. Visual examinations reminiscent of colonoscopies or sigmoidoscopies can discover and take away lesions or polyps that might grow to be cancer, stopping the disease.

“Most people would like a blood test that was more accurate in detecting not just cancer but also precancerous lesions. But the most remarkable thing about colorectal cancer screening is that people's willingness to do one test or the other varies,” Smith said. “You have to give people the choice.”

The-CNN-Wire
& © 2024 Cable News Network, Inc., a Warner Bros. Discovery company. All rights reserved.

By Chris Isidore | CNN

New York – Elon Musk and the Tesla board are facing a shareholder lawsuit for selling $7.5 billion price of Tesla shares in late 2022. The sale got here ahead of a January 2023 earnings report that sent the stock price plummeting.

musk A complete of 41.5 million Tesla shares were sold between Nov. 4 and Dec. 12, company filings show, as he liquidated a few of his holdings to unlock money for his recently accomplished purchase of Twitter.

The sales got here not long after a quarterly earnings call on October 19, 2022, by which he told investors, “I can't stress this enough, we have excellent demand for the fourth quarter.”

But when Tesla reported In the fourth quarter, sales were significantly weaker than forecast, leading to a 12% drop in share price, the worst trading day for the stock in greater than two years.

“Musk profited from his misconduct and the exploitation of material and detrimental inside information,” says the lawsuit filed by shareholder Michael Perry. The lawsuit demands that Musk repay the corporate the take advantage of the stock sale and reimburse Perry for his legal fees and other costs in filing the lawsuit.

Musk likely knew on the time of the sale that the weaker sales report was coming, the lawsuit says. Tesla cut its prices in China by as much as 9% on October 24, 2022, starting a Series of price reductions This has led to a drop in prices for electric vehicles from Tesla and other automakers within the face of weaker-than-forecast sales.

And in April last yr, Musk boasted about Tesla's cutting-edge sales figures – in comparison with automakers that don’t sell their vehicles on to customers but to a network of independent dealers.

“I'm not sure there's any company in the world that has better real-time data than Tesla, except maybe SpaceX Starlink,” he told investors on the time, referring to considered one of his other corporations.

Tesla stock sales financed Twitter purchase

But from April to December 2022, Musk sold $22.9 billion price of Tesla stock in unscheduled sales to spice up his Purchase price $44 billion of Twitter this yr.

His sales in November and December 2022, in addition to the value cuts in China, helped depress the value of Tesla shares even before the January sales report. His sale on November 4, 2022, was at a median price of $208.58, in keeping with filings with the Securities and Exchange Commission. His last sales of this group, on December 14, were at a median price of $158.37 that day.

But the fourth-quarter sales report in January, which was released on a Sunday, sent Shares fell from $123.18 to $108.10 on the close of trading last Friday.

However, Tesla shares soon recovered and greater than doubled over the course of 2023, closing at $248.48. But shares have struggled this yr, losing 29% of their value by Monday's close.

The lawsuit was filed Thursday in Delaware Chancery Court and first reported by BloombergTesla, which doesn’t have a public relations department, didn’t reply to a request for comment.

The lawsuit comes at a time when Tesla Obtaining shareholder approval to return the stock options to Musk that he withdrawn in a court decision in January in Delaware. Two influential consulting firms have called on shareholders to To vote against his controversial billion-dollar salary package and raised concerns concerning the CEO's quite a few side projects.

The-CNN-Wire
& © 2024 Cable News Network, Inc., a Warner Bros. Discovery company. All rights reserved.

Data from vaccine studies

The show would have blown Owsley “Bear” Stanley away.

Yes, even the famed LSD guru — who was also a sound engineer for the Grateful Dead and architect of the band's fabled “Wall of Sound” before his death in 2011 — could never have imagined such a full-force psychedelic rock experience as he expected fans on Thursday on the opening night of Dead & Company's “Dead Forever” run on the Sphere in Las Vegas.

They watched giant terrapins play instruments, rode around on a bike with a skeleton in patriotic clothing, and did dancing bears.

Oh yeah, and the music was pretty good too, like this phenomenally popular Grateful Dead offshoot – consisting of Dead alum Bob Weir on vocals and guitar and Mickey Hart on drums, in addition to singer-guitarist John Mayer and bassist Oteil Burbridge , keyboardist Jeff Chimenti and drummer Jay Lane – played through 19 songs in two very generous sets.

They took the stage promptly at 7:35 p.m. – just five minutes after the printed start time – and were still in top form almost 4 hours later.

It was an ideal option to rejoice the return to the stage for Dead & Company, the Bay Area-rooted jam band that wrapped up its blockbuster 2023 farewell tour with three sold-out shows at San Francisco's Oracle Park in July.

It was also the primary of 24 nights the band will perform on the Sphere, which has quickly grow to be arguably Las Vegas' landmark because the dome pulses with amazing video images that could be seen for miles. Fittingly, it featured the Dead's signature “Steal Your Face” skull logo and other graphics as fans entered the constructing on Thursday.

“Dead Forever” is the second residency to happen on the $2 billion venue, which opened in September with an epic performance by U2. Overall, Dead & Company is the third act to offer public concert events there – after their jam bandmate Phish took to the Sphere stage for 4 shows in April.

So what are Dead & Co. doing so soon after selling a whole lot of 1000’s of tickets for his or her farewell tour?

Well, technically the band just said goodbye to touring – and the Sphere residency isn't really a tour. So the band is grooving straight through that loophole and straight to the bank as they play shows through July 13, totally on weekends (deadandcompany.com).

The 18,000 or so fans in attendance actually weren't frightened about semantics or technical details, as they enjoyed hearing such long-time favorites as “Jack Straw,” “Bird Song” and “Brown-Eyed Women” during a comparatively short event – musically speaking – first movement.

After a half-hour break, the group heated up the second set with a robust jam from long-time music partners “Help on the Way,” “Slipknot!” and “Franklin’s Tower,” with the ultimate third arguably being the musical highlight of the whole show.

The graphics were nothing wanting exhilarating and sometimes disorienting – because the eyes tried to make sense of the near-constant sensory overload.

There were just a few moments where I felt a bit of dizzy and even felt a touch of motion sickness as I attempted in vain to soak up the whole lot that was happening on the large video screens because the band played “He's Gone” and “Standing On.” the moon” and “St. Stephen.”

The downside to being bombarded with all these computer graphics – and, well, just the big amount of sunshine – is that you just literally lose sight of the particular musicians. They visually grow to be afterthoughts of the whole lot that is happening.

Still, there have been moments when the whole lot got here together so well, like when the group returned to space to perform a poignant version of Bob Dylan's “Knockin' on Heaven's Door,” then accomplished the epic show with a triumphant run-through Buddy Holly's “Knockin' on Heaven's Door” closed. Don't fade.”

The Sphere truly offers a concert experience like no other. And there are very few, if any, bands that seem to fit what this venue has to offer better than Dead & Co.

Set list:
1. “Feel like a stranger”
2. “Mississippi Half-Step Uptown Toodeloo”
3. “Jack Straw”
4. “Birdsong”
5. “Me and my uncle”
6. “Brown-Eyed Women”
7. “Cold Rain and Snow”
Sentence 2:
8. “Uncle John’s Band”
9. “Help on the way”
10. “Slipknot!”
11. “Franklin’s Tower”
12. “He’s gone”
13. “Drums”
14. “Space”
15. “Standing on the Moon”
16. “St. Stephen”
17. “Hell in a Bucket”
18. “Klokin' on Heaven's Door”
19. “Don’t Fade”